Rodrigo Ochoa
Rodrigo Ochoa is an expert in Biochemistry at University of Antioquia (Colombia). Rodrigo Ochoa has authored 68 publications, the most recent in 2025, and is an investigator in 1 clinical trial, 1 of them ongoing. SLR score: 182 (community average: 125). How the SLR is computed.
LeadR Profile
Biochemistry
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2010 - 2025
Number : 68
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Trimerization domain-interfering peptide inhibits EML4-ALK condensate formation, fusion-dependent signaling, and cell growth. PMID 40875402 — cells, growth, molecular biology, neoplasms | Mol Biol Cell | 2025 | 0 |
| PepFuNN: Novo Nordisk Open-Source Toolkit to Enable Peptide in Silico Analysis. PMID 39777768 — amino acids, peptide library | J Pept Sci | 2025 | 0 |
| Targeting 7KCh-Induced Cell Death Response Mediated by p38, P2X7 and GSDME in Retinal Pigment Epithelium Cells with Sterculic Acid. PMID 38004569 — necrosis, cholesterol, cells, therapeutics, cell death, macular degeneration, retinal pigment epithelium, retina, retinal pigments, retinaldehyde | Pharmaceutics | 2023 | 0 |
| Assessing the fast prediction of peptide conformers and the impact of non-natural modifications. PMID 37659134 — amino acids | J Mol Graph Model | 2023 | 7 |
| pyPept: a python library to generate atomistic 2D and 3D representations of peptides. PMID 37700347 | J Cheminform | 2023 | 12 |
Clinical Studies 1
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Samarium Optimized for Long lasting Analgesia in Cancerous End stage Bone Pain NCT07197645 — safety, pain, neoplasms, radiopharmaceuticals, analgesia, neoplasm metastasis, bone neoplasms, bone and bones | Phase 1 | Recruiting | 2025 |
LeadR Networks
Main global connection map